Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents	Sanofi	Ongoing	HOE901 (insulin glargine)/ AVE0010 (lixisenatide) combination	IIIb	LPS15017	KFMC
Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial	King Saud Medical City	Completed	Colistin	4	KSMC-12-13	King Saud Medical City
"easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment"	Merck Serono	Rejected	-	4	200104-534	King Khalid University Hospital (Riyadh)
"AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)"	Alexion	Rejected	-	4	M11-001	N/A
A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome	Almarai	Rejected	Vetal Laban containing Lactobacillus acidophilus NCFM at 1.6 x 109 CFU per container	4	IBS - 0920	King Fahad Medical City (Riyadh)
"An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women"	Vifor Pharma	Terminated	Ferrous Sulphate + Ferinject	3	FER-ASAP-2009-01	King Faisal Specialist Hospital and Research Center (Riyadh)
The Effectiveness of Convalescent Plasma for the Treatment of Severe COVID-19 Cases in Intensive Care Unit	King Faisal Specialist Hospital and Research Centre	Ongoing	Convalescent Plasma	3	IRB 2020-19-V2	King Faisal Specialist Hospital and Research Center (Jeddah)
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis	Jamjoom Pharmaceuticals	Completed	Dexaflox	4	DEXA001	King Khalid University Hospital (Riyadh)
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions	Jamjoom Pharmaceuticals	Completed	Loxtra	4	LOX001	King Khalid University Hospital (Riyadh)
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Fluca Eye Drops Containing Sodium Cromoglycate (20 mg/ml) and Fluorometholone (1 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever	Jamjoom Pharmaceuticals	Completed	FLUCA	4	FLUCA001	King Khalid University Hospital (Riyadh)